Clinical Onco-immunology

Monday April 11
“Clinical Onco-Immunology” presented by Dr Jesse Stoff
Time:  8:30am to 5:30pm
Cost:  $499


The immune system has two critical functions: identify self from non-self and to destroy or eliminate non-self.  This can only work when the immune system and all its components are functioning optimally. Illness occurs when the elements of the immune system:

  1. incorrectly identifies an invader and/or attacks ‘self’ (auto-immune diseases such as ankylosing spondylitis, multiple sclerosis, fibromyalgia, CFS SLE and many more)
  2. fails to identify an invader (or wrongly manufactured cell such as cancer)
  3. is compromised due to poor nutrition, infection, trauma, toxicity or stress to the extent that it is unable to overcome the immune insult.

This presentation will cover some of the key aspects of pattern recognition of a T & B cell subset panel, based on the above, as it applies to treating patients with cancer. I will also present the latest information about the use of monoclonal antibodies singularly and in combination with other modalities including IPT.

Educational Objectives:

Participants will have the opportunity to learn:

  1. Basic interpretation of a commonly available comprehensive T & B cell subset panel.
  2. Basic pattern recognition of things that commonly compromise immune function.
  3. Initial therapeutic interventions that can address the patterns of immunological damage relative to the treatment of cancer.
  4. Protocols for immune reconstitution
  5. Protocols for immune activation
  6. Protocols for the use of monoclonal antibodies

Brief Biography:


Jesse A. Stoff, MD, MDH, FAAFP is an internationally renowned physician, with extensive credentials in immunology, naturopathy, homeopathy, acupuncture, and holistic medicine. He is a graduate of New York Medical College, and pursued post-doctoral training including a fellowship in Clinical Immunology. Since beginning his practice in 1986, he specializes in the use of cellular medicine for the treatment of his patients with severe and chronic diseases by activating specialized cells in the immune system and through the use of adult stem cells (since 1995) to stimulate the repair process. He has authored/co-authored dozens of articles and 8 books including co-authoring the bestsellers Chronic Fatigue Syndrome: The Hidden Epidemic and The Prostate Miracle. He has also served as a member of the Clinical Nutrition Board of Cancer Treatment Centers of America, Inc. As Medical Director of the Stoff Institute for Medical Research, he consults with physicians and medical groups both domestically and abroad on the subjects of immune system disorders and immune reconstitution. As a result of his research he has developed several new molecular complexes, one of which is now being patented as a true anti-biotic replacement (see PMID: 17190737)

Dr. Stoff’s practice covers many aspects of immune-therapy through cellular medicine. Please see his website at:

Chief Science Officer Immune Biologics (Scottsdale, AZ 2001-current)

Overview of responsibilities: Basic science research in the discovery of Bio-Engineered Lacteal Complex.


  • Discovered Bio-Engineered Lacteal Complex (BLC), a pathogen specific biological complex with 5 mechanisms of action that represents a new class of biologic antibiotics and includes a provision for the treatment of cancer.
  • Delineated the protocols for producing, processing, assaying and administering BLC.
  • Patents filed in 7 different classes for producing, processing and assaying BLC.
  • Manuscript published in Immunopharmacology and Immunotoxicology.

Advanced Clinical Immunology Work With:

Dr. George Olson, Professor Emeritus, University of Arizona, Immunology 1991-1996 (External clinical Fellowship)
Dr. Ben Papermaster 1995-1999 Collaborative research on TNF-B

Note: Lectures  given at:

 “III Curso Internacional de Immunocompromiso”, Hospital General, Mexico City, Mexico.

 “Immune  Reconstitution with Cytokines and Similar Agents”, May 14, 1999.

 “Immune  Reconstitution with Targeted Human Umbilical Cord Stem Cells”, May 15,  1999.

As a result of  these lectures I consulted in the construction and operation of a HUCB (human umbilical cord blood)Stem Cell clinic there for 2 years. During that time I developed a number of successful protocols for the therapeutic application of targeted HUCB stem cells for people auto-immune diseases, multiple sclerosis and ALS. I also developed a combination of therapies using a dendritic cell vaccine and cytokine induced killer cells for people with cancer.

Patent filed for producing, processing and assaying BLC, under the heading of:  IMMUNODYNAMIC COMPLEXES AND METHODS FOR USING AND PREPARING SUCH COMPLEXES

 See: Journal: LIPI: Immunopharmacology and Immunotoxicology

 Manuscript ID: 206636

 Manuscript Title: A Pilot Study of an anti-MRSA Bio-Engineered Lacteal Complex

 (anti-MRSA BLC) in a Murine Septicemia Model

  Vol 28 No 4/Oct-Dec 2006   By: Stoff; Nix; DeYoung